Study Shows Antitussive Efficacy For Diphenhydramine, Less For DXM
This article was originally published in The Tan Sheet
Executive Summary
Diphenhydramine, a common antihistamine in cough/cold OTCs, proves more effective in suppressing cough than the common antitussive dextromethorphan, researchers say. Diphenhydramine is in FDA’s antitussive OTC monograph, but marketers are criticized for not demonstrating its and other cough/cold ingredients’ efficacy in trials.
You may also be interested in...
Developing Antitussive Alternatives To DXM Would Offset Commercial Risk
Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.